The difference in docking scores (−6.52 vs. −5.47) suggests that Celecoxib has a higher therapeutic potential for targeting PDK1, particularly in AD and ALS, where pyruvate metabolism is a key pathological feature. This evidence concerns the gene PDK1 and Alzheimer disease.